Trial Profile
A Prospective, Single-Arm Study to Evaluate the Efficacy and Safety of Abraxane Combined With Epirubicin as Neoadjuvant Chemotherapy in Early Operable Breast Cancer
Status:
Not yet recruiting
Phase of Trial:
Phase 0
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Epirubicin (Primary) ; Paclitaxel (Primary)
- Indications Early breast cancer; Male breast cancer
- Focus Therapeutic Use
- 21 Nov 2018 Planned initiation date changed from 1 Oct 2018 to 1 Dec 2018.
- 03 Sep 2018 New trial record